Lipopolysaccharide induces cellular hypertrophy through calcineurin/NFAT-3 signaling pathway in H9c2 myocardiac cells

ASIA unversity > 醫學暨健康學院 > 生物科技學系 > 期刊論文 > Item 310904400/16106

Please use this identifier to cite or link to this item: http://asiair.asia.edu.tw/ir/handle/310904400/16106

Title:	Lipopolysaccharide induces cellular hypertrophy through calcineurin/NFAT-3 signaling pathway in H9c2 myocardiac cells
Authors:	Liu, Chung-Jung;Cheng, Yi-Chang;Lee, Kung-Wei;Hsu, Hsi-Hsien;Chu, Chun-Hsien;Tsai, Fuu-Jen;Tsai, Chang-Hai;Chu, Chia-Yih;Liu, Jer-Yuh;Kuo, Wei-Wen;黃志揚;HUANG, CHIH-YANG
Contributors:	生物科技學系
Keywords:	Lipopolysaccharide;Myocardiac cell;Hypertrophy;Calcineurin;NFAT-3;GATA-4
Date:	2008
Issue Date:	2012-11-23 09:08:37 (UTC+0)
Abstract:	Evidences suggest that lipopolysaccharide (LPS) participates in the inflammatory response in the cardiovascular system; however, it is unknown if LPS is sufficient to cause the cardiac hypertrophy. In the present study, we treated H9c2 myocardiac cells with LPS to explore whether LPS causes cardiac hypertrophy, and to identify the precise molecular and cellular mechanisms behind hypertrophic responses. Here we show that LPS challenge induces pathological hypertrophic responses such as the increase in cell size, the reorganization of actin filaments, and the upregulation of hypertrophy markers including atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) in H9c2 cells. LPS treatment significantly promotes the activation of GATA-4 and the nuclear translocation of NFAT-3, which act as transcription factors mediating the development of cardiac hypertrophy. After administration of inhibitors including U0126 (ERK1/2 inhibitor), SB203580 (p38 MAPK inhibitor), SP600125 (JNK1/2 inhibitor), CsA (calcineurin inhibitor), FK506 (calcineurin inhibitor), and QNZ (NFκB inhibitor), LPS-induced hypertrophic characteristic features, such as increases in cell size, actin fibers, and levels of ANP and BNP, and the nuclear localization of NFAT-3 are markedly inhibited only by calcineurin inhibitors, CsA and FK506. Collectively, these results suggest that LPS leads to myocardiac hypertrophy through calcineurin/NFAT-3 signaling pathway in H9c2 cells. Our findings further provide a link between the LPS-induced inflammatory response and the calcineurin/NFAT-3 signaling pathway that mediates the development of cardiac hypertrophy
Relation:	MOLECULAR AND CELLULAR BIOCHEMISTRY
Appears in Collections:	[生物科技學系] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	427	View/Open

Loading...